We are hereby submitting the monitoring agency report for the quarter ended 31st March, 2026
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Kilitch Drugs India raised Rs. 49.92 crore via a Rights Issue in Q2FY26 (July–August 2025). The monitoring agency, Infomerics Valuation and Rating Limited, confirms no material deviation in the utilization of proceeds as of Q4FY26. Rs. 47 crore was earmarked for capex on a Greenfield manufacturing project at Pen, Maharashtra, of which Rs. 40.35 crore has been deployed, leaving Rs. 6.65 crore still available for the project. Rs. 1.12 crore from the General Corporate Purposes (GCP) bucket remains unutilized and is now expected to be deployed in Q1FY27, as certain capex-related payments are pending due to a pending final inspection of the project. The unutilized amount is currently parked in FDs with Kotak Mahindra Bank earning 6.35% interest. Statutory auditors M/s. C. Sharat & Associates have verified the utilization with no deviations reported.
The report is broadly positive for shareholders — funds are being deployed largely as planned for the Greenfield expansion project, and the Rs. 1.12 crore delay is minor and explained by operational reasons (pending project inspection), not financial distress. No red flags for the rights issue investment.